Affordable Access

deepdyve-link
Publisher Website

The implications of baseline bone-health assessment at initiation of androgen-deprivation therapy for prostate cancer.

Authors
  • Kirk, Peter S1
  • Borza, Tudor1
  • Shahinian, Vahakn B2
  • Caram, Megan E V3, 4
  • Makarov, Danil V5, 6
  • Shelton, Jeremy B7
  • Leppert, John T8, 9
  • Blake, Ryan M1
  • Davis, Jennifer A4
  • Hollenbeck, Brent K1
  • Sales, Anne4, 10
  • Skolarus, Ted A1, 4
  • 1 Dow Division of Health Services Research, Department of Urology, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 2 Division of Nephrology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 3 Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan Health System, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 4 Veterans Affairs (VA) Health Services Research and Development, Center for Clinical Management Research, VA Ann Arbor Healthcare System, University of Michigan Medical School, Ann Arbor, MI, USA.
  • 5 Departments of Urology and Population Health, NYU Langone Medical Center, New York City, NY, USA.
  • 6 VA New York Healthcare System, New York City, NY, USA.
  • 7 VA Greater Los Angeles Healthcare System, Los Angeles City, LA, USA.
  • 8 Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.
  • 9 VA Palo Alto Healthcare System, Palo Alto, CA, USA.
  • 10 Department of Learning Health Sciences, University of Michigan Medical School, Ann Arbor, MI, USA.
Type
Published Article
Journal
British Journal of Urology
Publisher
Wiley (Blackwell Publishing)
Publication Date
Nov 10, 2017
Identifiers
DOI: 10.1111/bju.14075
PMID: 29124881
Source
Medline
Keywords
License
Unknown

Abstract

BDT is rare amongst patients with prostate cancer treated with ADT in this integrated delivery system. However, BDT was associated with substantially increased treatment of osteoporosis indicating an underappreciated burden of osteoporosis amongst prostate cancer survivors initiating ADT. Optimising BDT use and osteoporosis management in this at-risk population appears warranted.

Report this publication

Statistics

Seen <100 times